Vadadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor used to treat symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production.
- Mechanism
- Curator reviewed · 4 references
Hypoxia-inducible factors (HIFs) are transcription factors responsible for cellular survival under hypoxic conditions. They regulate a number of processes including angiogenesis, cell growth and differentiation, various metabolic processes, and erythropoiesis. Under normoxic conditions, HIFs are degraded via hydroxylation by prolyl-hydroxylase dioxygenases.
Vadadustat is an inhibitor of HIF-prolyl-hydroxylases (HIF-PHI), that facilitates increased HIF activity in the absence of hypoxic conditions. The increased levels of HIF prompted by vadadustat stimulate endogenous erythropoietin production, increasing iron mobilization and contributing to the gradual rise of hemoglobin levels and the correction of iron metabolism. In patients with anemia of chronic kidney disease, in whom normal erythropoiesis is dysfunctional, this leads to the correction of anemia.
- Primary indication
- Vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.Curator reviewed · 2 structured indications
- Formula / weight
- C14H11ClN2O4 · 306.7 g/mol (avg)
- First approval
- United States, 2024 · European Union, 2023
- Code names
- AKB-6548 · B-506 · PG-1016548
- Brand names
Resolves to
JGRXMPYUTJLTKT-UHFFFAOYSA-NSMILESOC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1What you can answer from here — as of April 03, 2024
Which drugs share a target with Vadadustat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account